United Therapeutics seeks IPF approval for Tyvaso
United Therapeutics Corporation (NASDAQ:UTHR) announced that the FDA accepted its supplemental New Drug Application for nebulized Tyvaso (treprostinil) Inhalation Solution as a potential treatment for idiopathic pulmonary fibrosis (IPF).










